Balthaser Kevin 4

What Happened
Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics (ACRS), had 22,025 restricted stock units (RSUs convert/vest) settle into common shares on February 3, 2026. To satisfy tax withholding, 6,449 of those shares were withheld (disposed) at $3.47 per share for a withholding amount of $22,378, leaving a net receipt of 15,576 shares. This was a vesting/settlement of an equity award rather than an open-market buy or sell.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely within SEC reporting window).
• Conversion/settlement: 22,025 RSUs converted to 22,025 shares (reported as derivative conversion).
• Tax withholding: 6,449 shares withheld at $3.47/share = $22,378 paid to cover taxes (code F).
• Net shares delivered to insider: 15,576 shares (22,025 − 6,449).
• Footnotes: F1–F3 indicate these were RSUs (one share per unit), shares were withheld to satisfy tax withholding, and the award vests in four equal annual installments beginning Feb 3, 2026 (this transaction reflects one installment).
• Shares owned after transaction: not stated in the filing.

Context
This was a routine RSU vesting and cashless tax withholding, not an open-market sale or purchase. For retail investors, vesting/withholding transactions are common compensation events and do not by themselves signal trading intent. The filing appears timely and no 10b5-1 plan or late-filing flag is indicated.